However, a few studies have suggested that the recurrence and death rate ratio is independent of PgR status in ER-positive (ER+) disease treated with adjuvant tamoxifen and that luminal A and B tumours similarly benefit from endocrine therapy regardless of PgR expression [5,6]. Here, PGR is linked to neoplasm.